Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings data on Tuesday. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12, Zacks reports. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same quarter in the previous year, the firm earned $0.89 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock traded down $0.36 during trading on Thursday, hitting $23.24. 91,111 shares of the company’s stock were exchanged, compared to its average volume of 597,128. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -259.30, a PEG ratio of 0.73 and a beta of 1.17. The business has a 50-day simple moving average of $23.74 and a 200-day simple moving average of $21.84. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $41.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 3.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley assumed coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.